Leucine-rich repeat kinase 2 (LRRK2) is a highly pursued drug target for Parkinson’s disease (PD), which is the second most common neurodegenerative disease projected to affect 17.5 million people by 20401. This evidence concerns the gene LRRK2 and neurodegenerative disease.